malic acid has been researched along with Autoimmune Diabetes in 2 studies
malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.
2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alloxan and oxidative stress, which have been detected in livers of laboratory animals shortly after in vivo alloxan administration, cause in vitro mitochondrial dysfunction, thus questioning alloxan diabetes as an acceptable model for type 1 diabetes, a model that cannot legitimately be used to investigate mitochondrial metabolism in a diabetic state." | 7.77 | Early hyperglycemia following alloxan administration in vivo is not associated with altered hepatic mitochondrial function: acceptable model for type 1 diabetes? ( Alvarez-Bustamante, JA; Rendon, DA, 2011) |
| "Alloxan and oxidative stress, which have been detected in livers of laboratory animals shortly after in vivo alloxan administration, cause in vitro mitochondrial dysfunction, thus questioning alloxan diabetes as an acceptable model for type 1 diabetes, a model that cannot legitimately be used to investigate mitochondrial metabolism in a diabetic state." | 3.77 | Early hyperglycemia following alloxan administration in vivo is not associated with altered hepatic mitochondrial function: acceptable model for type 1 diabetes? ( Alvarez-Bustamante, JA; Rendon, DA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vigers, T | 1 |
| Vinovskis, C | 1 |
| Li, LP | 1 |
| Prasad, P | 1 |
| Heerspink, H | 1 |
| D'Alessandro, A | 1 |
| Reisz, JA | 1 |
| Piani, F | 1 |
| Cherney, DZ | 1 |
| van Raalte, DH | 1 |
| Nadeau, KJ | 1 |
| Pavkov, ME | 1 |
| Nelson, RG | 1 |
| Pyle, L | 1 |
| Bjornstad, P | 1 |
| Rendon, DA | 1 |
| Alvarez-Bustamante, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CASPER Study: Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function[NCT03618420] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study[NCT03584217] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2018-10-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured by fasting blood draw; Copeptin will be measured by ultrasensitive assays on KRYPTOR Compact Plus analyzers using the commercial sandwich immunoluminometric assays (Thermo Fisher Scientific, Waltham, MA). The copeptin assay has a lower limit of detection of 0.9 pmol/L, and a sensitivity of <2pmol/L. Elevated copeptin will be defined as >13pmol/L, which is >97.5th percentile for healthy adults (68). (NCT03618420)
Timeframe: 4 hours
| Intervention | pmol/L (Mean) |
|---|---|
| Clinical Investigation | 8.3 |
Measured by para-aminohippurate (PAH) clearance; An intravenous (IV) line was placed, and participants were asked to empty their bladders. Spot plasma and urine samples were collected prior PAH infusion. PAH (2 g/10 mL, prepared at the University of Minnesota, with a dose of [weight in kg]/75 × 4.2 mL; IND #140129) was given slowly over 5 min followed by a continuous infusion of 8 mL of PAH and 42 mL of normal saline at a rate of 24 mL/h for 2 h. After an equilibration period, blood was drawn at 90 and 120 min, and ERPF was calculated as PAH clearance divided by the estimated extraction ratio of PAH, which varies by the level of GFR (13). We report absolute ERPF (mL/min) in the main analyses because the practice of indexing ERPF for body surface underestimates hyperperfusion, and body surface area (BSA) calculations introduce noise into the clearance measurements. (NCT03618420)
Timeframe: 4 hours
| Intervention | ml/min (Mean) |
|---|---|
| Clinical Investigation | 820 |
Measured by iohexol clearance; An intravenous (IV) line was placed, and participants were asked to empty their bladders. Spot plasma and urine samples were collected prior to iohexol infusion. Iohexol was administered through bolus IV injection (5 mL of 300 mg/mL; Omnipaque 300, GE Healthcare). An equilibration period of 120 min was used and blood collections for iohexol plasma disappearance were drawn at +120, +150, +180, +210, +240 min (11). Because the Brøchner-Mortensen equation underestimates high values of GFR, the Jødal-Brøchner-Mortensen equation was used to calculate the GFR (12). We report absolute GFR (mL/min) in the main analyses because the practice of indexing GFR for body surface underestimates hyperfiltration, and body surface area (BSA) calculations introduce noise into the clearance measurements. (NCT03618420)
Timeframe: 4 hours
| Intervention | ml/min (Mean) |
|---|---|
| Clinical Investigation | 189 |
Measured by Blood Oxygen Level Dependent (BOLD) MRI; Regions of interest (ROI) analysis for BOLD MRI will be performed on a Leonardo Workstation (Siemens Medical Systems, Germany). Typically, 1 to 3 regions in each, cortex and medulla, per kidney per slice will be defined leading to a total of about 10 ROIs per region (cortex and medulla) per subject. The mean and standard deviation of these 10 measurements will be used a R2* measurement for the region, for the subject and for that time point. These data are used to calculate kidney oxygen availability (R2*), which is the BOLD-MRI outcome. (NCT03618420)
Timeframe: 60 min
| Intervention | s^-1 (Mean) |
|---|---|
| Clinical Investigation | 22.7 |
Measured by Arterial Spin Labeling (ASL) MRI; ASL MRI: ROI analysis will be used to estimate (delta) M (difference in signal intensity between non-selective and selective inversion images). Using the same ROI, M0 will be estimated from the proton density image. T1 measurements from the same ROI will be obtained by fitting the signal intensity vs. inversion time data as described previously (104) using XLFit (ID Business Solutions Ltd., UK) or T1 maps created using MRI Mapper (Beth Israel Deaconess Medical Center, Boston). Partition coefficient will be assumed to be 0.8 ml/gm (105, 106). These values will then be used to estimate regional blood flow. (NCT03618420)
Timeframe: 10 min
| Intervention | ml/min/100g (Mean) |
|---|---|
| Clinical Investigation | 180 |
1 trial available for malic acid and Autoimmune Diabetes
| Article | Year |
|---|---|
Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes.
Topics: Adolescent; Albuminuria; Carboxylic Acids; Diabetes Mellitus, Type 1; Fumarates; Glomerular Filtrati | 2023 |
Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes.
Topics: Adolescent; Albuminuria; Carboxylic Acids; Diabetes Mellitus, Type 1; Fumarates; Glomerular Filtrati | 2023 |
Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes.
Topics: Adolescent; Albuminuria; Carboxylic Acids; Diabetes Mellitus, Type 1; Fumarates; Glomerular Filtrati | 2023 |
Plasma levels of carboxylic acids are markers of early kidney dysfunction in young people with type 1 diabetes.
Topics: Adolescent; Albuminuria; Carboxylic Acids; Diabetes Mellitus, Type 1; Fumarates; Glomerular Filtrati | 2023 |
1 other study available for malic acid and Autoimmune Diabetes
| Article | Year |
|---|---|
Early hyperglycemia following alloxan administration in vivo is not associated with altered hepatic mitochondrial function: acceptable model for type 1 diabetes?
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease | 2011 |